The interplay of knowledge, motivation, and treatment response in medication adherence among patients with chronic myeloid leukemia treated with Imatinib

被引:0
|
作者
Omran, Mervat M. [1 ]
Ibrahim, Amel B. [2 ]
Abdelfattah, Raafat [3 ]
Moussa, Heba S. [4 ]
Shouman, Samia A. [1 ]
Hamza, Marwa S. [5 ]
机构
[1] Cairo Univ, NCI, Canc Biol Dept, Pharmacol Unit, Kasr Al Eini St, Cairo 11796, Egypt
[2] Zawia Univ, Fac Med, Dept Pharmacol, Az Zawiyah, Libya
[3] Cairo Univ, NCI, Med Oncol Dept, Cairo, Egypt
[4] Cairo Univ, NCI, Clin Pathol Dept, Cairo, Egypt
[5] British Univ Egypt, Fac Pharm, Clin Pharm Practice Dept, El Sherouk City, Cairo, Egypt
关键词
Imatinib mesylate; CML; adherence; trough; peak; CHRONIC MYELOGENOUS LEUKEMIA; CYTOGENETIC RESPONSES; TYROSINE KINASE; BLAST CRISIS; THERAPY; NONADHERENCE; OUTCOMES;
D O I
10.1080/10428194.2024.2403671
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic Myeloid Leukemia (CML) requires consistent medication adherence to Imatinib (IM) for optimal outcomes, however, adherence to oral chemotherapy is challenging. This observational study explores the relationship between patient knowledge, motivation, and adherence to IM therapy, and their collective impact on clinical outcomes. A prospective, observational study was conducted with 101 CML patients. The 6-Item Morisky Medication Adherence Scale (MMAS-6) was used to assess adherence, motivation, and knowledge levels. The study found that high motivation was significantly associated with lower BCR-ABL expression (p = 0.025). Patients with high knowledge and motivation had a 71% favorable response rate, compared to 0% in those with low knowledge and motivation (p = 0.01). As conclusion both patient motivation and knowledge are crucial for favorable treatment outcomes in CML. High levels of both significantly correlate with better clinical responses. Tailored interventions to enhance patient knowledge and motivation are essential.
引用
收藏
页码:123 / 130
页数:8
相关论文
共 50 条
  • [31] Immunoprofile of Patients with Chronic Myeloid Leukemia Treated with Imatinib, Nilotinib or Dasatinib
    Hayashi, Yoshiki
    Nakamae, Hirohisa
    Katayama, Takako
    Nakane, Takahiko
    Koh, Hideo
    Nishimoto, Mitsutaka
    Nakamae, Mika
    Yoshida, Masahiro
    Bingo, Masato
    Okamura, Hiroshi
    Aimoto, Mizuki
    Manabe, Masahiro
    Yoshimura, Takuro
    Inaba, Akiko
    Nanno, Satoshi
    Hagihara, Kiyoyuki
    Nakao, Yoshitaka
    Terada, Yoshiki
    Hino, Masayuki
    BLOOD, 2011, 118 (21) : 1607 - 1607
  • [32] Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate
    Arora, B
    Kumar, L
    Sharma, A
    Wadhwa, J
    Kochupillai, V
    ANNALS OF ONCOLOGY, 2004, 15 (02) : 358 - 359
  • [33] Nutritional Status of Patients with Chronic Myeloid Leukemia Treated with Imatinib Mesylate
    Jose Castillo-Martinez, Maria
    Juventina Tuna-Aguilar, Elena
    del Pilar Milke-Garcia, Maria
    Camacho Zamora, Anais
    Villegas Cervantes, Viviana
    Castillo-Martinez, Lilia
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2022, 74 (09): : 3211 - 3216
  • [34] Temporal effect of imatinib adherence on time to remission in chronic myeloid leukemia patients
    Clark, Samantha E.
    Marcum, Zachary A.
    Radich, Jerry
    Etzioni, Ruth
    Basu, Anirban
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (08) : 1343 - 1351
  • [35] Ocular side effects in chronic myeloid leukemia patients treated with Imatinib
    Breccia, M.
    Latagliata, R.
    Carmosino, I
    Cannella, L.
    Levi, A.
    Frustaci, A.
    Stefanizzi, C.
    Volpicelli, P.
    Alimena, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 183 - 183
  • [36] Patients' Perspectives on Adherence to Treatment in Chronic Myeloid Leukemia
    Normen, Michelle
    Surendran, V
    Ganesan, Prasanth
    Rajendranath, Rejiv
    Sagar, T. G.
    PSYCHO-ONCOLOGY, 2013, 22 : 213 - 213
  • [37] miRNA in chronic myeloid leukemia and imatinib response
    Dulucq, Stephanie
    Mahon, Francois Xavier
    PHARMACOGENOMICS, 2010, 11 (09) : 1201 - 1202
  • [38] XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia
    Guillem, Vicent M.
    Cervantes, Francisco
    Martinez, Jesus
    Alvarez-Larran, Alberto
    Collado, Maria
    Camos, Mireia
    Sureda, Anna
    Maffioli, Margherita
    Marugan, Isabel
    Hernandez-Boluda, Juan-Carlos
    AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (07) : 482 - 486
  • [39] Treatment of Chronic Phase Chronic Myeloid Leukemia with Imatinib
    Ganesan, Prasanth
    Rajendranath, Rejiv
    Kandakumar, Vignesh
    Sagar, Tenali Gnana
    INDIAN JOURNAL OF PEDIATRICS, 2015, 82 (03): : 235 - 239
  • [40] Treatment of Chronic Phase Chronic Myeloid Leukemia with Imatinib
    Prasanth Ganesan
    Rejiv Rajendranath
    Vignesh Kandakumar
    Tenali Gnana Sagar
    The Indian Journal of Pediatrics, 2015, 82 : 235 - 239